Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
    ACCESS Newswire

    GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

    September 25, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    ANKARA, TURKEY / ACCESSWIRE / September 25, 2024 / GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. The findings were presented at Amsterdam’s European Academy of Dermatology and Venereology (EADV) 2024 Congress.

    GEN Pharmaceuticals
    GEN Pharmaceuticals
    GEN Pharmaceuticals Manufacturing Facility

    This multicenter, randomized, double-blind, placebo-controlled Phase 2 study involved 190 patients across 19 clinical centers in Türkiye. Patients were treated with GN-037, clobetasol 17-propionate, or placebo twice daily for four weeks, followed by an additional four-week observation period. The study demonstrated GN-037’s statistically significant superiority in reducing psoriasis symptoms compared to placebo, positioning it as a promising new treatment option for psoriasis patients worldwide.

    Key Findings:

    • The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator’s Global Assessment (IGA) score and achieving an IGA score of 0 or 1.
    • 37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006).
    • GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008), plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo.
    • 31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009).
    • No new safety concerns emerged with similar treatment-emergent adverse events across all arms.

    Abidin Gülmüş, Chairman of GEN, stated:
    “We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community.”

    Nadir Ulu, MD, PhD, Vice President of R&D, added:
    “Our Phase 2 trial results highlighted GN-037’s potential to improve patient outcomes significantly, and it may provide a novel, well-tolerated treatment option for patients with mild to moderate plaque psoriasis.”

    About GEN:
    Founded in 1998, GEN is Türkiye’s leading speciality pharmaceutical company. It is focused on developing innovative therapies across multiple therapeutic areas, with significant R&D investments and a commitment to advancing global healthcare. GEN actively works in both in-licensing and out-licensing business models. GEN partners with leading global pharmaceutical companies to bring innovative therapies and rare solutions to communities in its countries. It also develops and produces highly demanded and competitive therapeutic products in its GMP-certified manufacturing facility to bring therapy solutions required in international markets.

    For more information, visit www.genilac.com.tr.

    For inquiries:
    Bulutay GÜNEŞ, Head of Corporate Brand, b.gunes@genilac.com
    Ali KETENCİOĞLU, Investor Relations Manager, a.ketencioglu@genilac.com

    Contact Information

    Bulutay Güneş
    Head of Corporate Brand
    b.gunes@genilac.com

    Ali Ketencioğlu
    Investor Relations Manager
    a.ketencioglu@genilac.com

    SOURCE: GEN Pharmaceuticals

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026
    Latest News

    Guinea declares mpox outbreak over after 42 days without cases

    Health November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.